Marie-Claire is a Partner on the Pfizer Ventures Team and an Executive Director in Emerging Science & Innovation at Pfizer. In her current role she is responsible for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. She is on the Board of Directors for DEM Biopharma and Grey Wolf Therapeutics.
Marie-Claire holds a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University and has spent 25 years at Pfizer holding various leadership positions supporting small molecule discovery. As part of her former responsibilities, Marie-Claire founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), and ten additional therapeutics that are currently in clinical trials. She has additional experience leading compound management, high throughput ADME, data support and management, genetically modified models, preclinical bioimaging and biobanking.
Marie-Claire was recognized as a PhRMA ‘We Work For Health’ Champion in 2018 and was a 2019 finalist for the CT Women of Innovation Award. She is active on multiple community non-profit boards and is the Executive Sponsor for the Pfizer Women’s Resource Group in CT.